News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,636 Results
Type
Article (39049)
Company Profile (279)
Press Release (646308)
Section
Business (203872)
Career Advice (1991)
Deals (35365)
Drug Delivery (85)
Drug Development (80799)
Employer Resources (168)
FDA (16087)
Job Trends (14805)
News (344554)
Policy (32437)
Tag
Academia (2530)
Alliances (49089)
Alzheimer's disease (1229)
Approvals (16021)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11534)
Biotechnology (200)
Breast cancer (120)
Cancer (1086)
Cardiovascular disease (97)
Career advice (1660)
Cell therapy (234)
Clinical research (64247)
Collaboration (388)
Compensation (200)
COVID-19 (2530)
C-suite (94)
Data (1126)
Diabetes (152)
Diagnostics (6139)
Earnings (84821)
Employer resources (146)
Events (109490)
Executive appointments (310)
FDA (16625)
Funding (351)
Gene therapy (178)
GLP-1 (576)
Government (4325)
Healthcare (18669)
Infectious disease (2615)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16297)
Job creations (3624)
Job search strategy (1417)
Layoffs (412)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19143)
Metabolic disorders (401)
Neuroscience (1504)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1480)
Obesity (231)
Opinion (179)
Patents (102)
People (56275)
Phase I (19955)
Phase II (28302)
Phase III (21096)
Pipeline (458)
Postmarket research (2553)
Preclinical (8494)
Radiopharmaceuticals (236)
Rare diseases (219)
Real estate (5890)
Regulatory (21523)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1301)
Startups (3563)
United States (13474)
Vaccines (548)
Weight loss (167)
Date
Today (128)
Last 7 days (689)
Last 30 days (3716)
Last 365 days (35652)
2024 (32713)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37554)
2014 (31327)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27330)
Location
Africa (713)
Arizona (192)
Asia (37120)
Australia (6058)
California (3325)
Canada (1293)
China (249)
Colorado (146)
Connecticut (152)
Europe (79525)
Florida (460)
Georgia (116)
Illinois (341)
Indiana (196)
Kansas (96)
Maryland (575)
Massachusetts (2608)
Michigan (157)
Minnesota (273)
New Jersey (954)
New York (961)
North Carolina (701)
Northern California (1480)
Ohio (139)
Pennsylvania (844)
South America (1091)
Southern California (1301)
Texas (463)
Utah (90)
Washington State (361)
685,636 Results for "agendia inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Agendia®, Inc., announced that new data on its comprehensive genomic tests will be presented at the American Society of Clinical Oncology Annual Meeting, taking place May 31st – June 4th, 2024, in Chicago, Illinois.
May 24, 2024
·
5 min read
Biotech Beach
Agendia to Present New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer at 2024 ASCO
Agendia ® , Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two different chemotherapy regimens.
May 31, 2024
·
5 min read
Biotech Beach
Agendia Announces New Data Assessing the Immune Active State in HR+/HER2- Early-Stage Breast Cancer at 2024 ASCO
Agendia ® , Inc. today announced it will present new data characterizing the immune biology of MammaPrint High Risk tumors in an oral session at the 2024 Annual American Society of Clinical Oncology (ASCO) Meeting , taking place in Chicago, IL. on June 3rd, 2024.
May 31, 2024
·
5 min read
Biotech Beach
Agendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint®
Agendia®, Inc., announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled.
February 1, 2024
·
4 min read
Biotech Beach
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
Agendia®, Inc. announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.
March 20, 2024
·
4 min read
Biotech Beach
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
Agendia®, Inc., announced it will share new data from the ongoing prospective, observational FLEX Trial in two poster presentations at the 41st Annual Miami Breast Cancer Conference, taking place March 7 – 10th, 2024.
March 8, 2024
·
6 min read
Press Releases
Agendia’s FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population
September 12, 2024
·
5 min read
Business
Agendia Appoints Ronald Andrews and David Schreiber to Board of Directors
Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, announced the appointment of industry veterans Ronald Andrews and David Schreiber to the company’s Board of Directors.
June 14, 2023
·
4 min read
Biotech Beach
German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines
Agendia®, Inc. announced that the company’s 80-gene molecular subtyping assay, BluePrint®, is now included in the latest version of German Gynecological Oncology Group guidelines.
April 11, 2024
·
5 min read
Biotech Beach
Agendia Studies Reveal the Influence of Race on a Tumor’s Biology, Reinforcing its Commitment to Advancing Research of Racial Disparities in Breast Cancer
At the 2023 ASCO Annual Meeting, Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, reinforces its commitment to progressing research of racial disparities in breast cancer through two poster presentations.
May 31, 2023
·
5 min read
1 of 68,564
Next
